APC is altered in 2.2% of medulloblastoma patients [4].

APC Loss is an inclusion criterion in 7 clinical trials for medulloblastoma, of which 7 are open and 0 are closed. Of the trials that contain APC Loss and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (3 open), 1 is phase 4 (1 open), and 1 is no phase specified (1 open) [5].

APC Loss is an inclusion criterion in 3 clinical trials for familial adenomatous polyposis, of which 2 are open and 1 is closed. Of the trials that contain APC Loss and familial adenomatous polyposis as inclusion criteria, 1 is phase 2 (1 open) and 2 are phase 3 (1 open) [5].

APC Loss is an inclusion criterion in 3 clinical trials for medulloblastoma, non-WNT/non-SHH, of which 3 are open and 0 are closed. Of the trials that contain APC Loss and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [5].

APC Loss is an inclusion criterion in 3 clinical trials for medulloblastoma, WNT-activated, of which 3 are open and 0 are closed. Of the trials that contain APC Loss and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].

APC is altered in 3.88% of anaplastic astrocytoma patients [4].

APC Loss is an inclusion criterion in 2 clinical trials for anaplastic astrocytoma, of which 1 is open and 1 is closed. Of the trials that contain APC Loss and anaplastic astrocytoma as inclusion criteria, 2 are phase 1 (1 open) [5].

APC is altered in 1.98% of central nervous system embryonal neoplasm patients [4].

APC Loss is an inclusion criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain APC Loss and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

APC Loss is an inclusion criterion in 2 clinical trials for central nervous system ganglioneuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain APC Loss and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

APC Loss is an inclusion criterion in 2 clinical trials for central nervous system neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain APC Loss and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

APC is altered in 5.26% of desmoplastic/nodular medulloblastoma patients [4].

APC Loss is an inclusion criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain APC Loss and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [5].

APC is altered in 3.04% of glioblastoma patients [4].

APC Loss is an inclusion criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain APC Loss and glioblastoma as inclusion criteria, 2 are phase 1 (1 open) [5].

APC Loss is an inclusion criterion in 2 clinical trials for large cell/anaplastic medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain APC Loss and large cell/anaplastic medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [5].

APC Loss is an inclusion criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain APC Loss and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [5].

APC Loss is an inclusion criterion in 2 clinical trials for medulloepithelioma, of which 2 are open and 0 are closed. Of the trials that contain APC Loss and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

APC is altered in 1.89% of lymphoma patients with APC Loss present in 0.42% of all lymphoma patients [4].

APC Loss is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains APC Loss and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

APC is altered in 65.55% of colorectal carcinoma patients with APC Loss present in 0.36% of all colorectal carcinoma patients [4].

APC Loss is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains APC Loss and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

APC is altered in 3.19% of ovarian carcinoma patients with APC Loss present in 0.25% of all ovarian carcinoma patients [4].

APC Loss is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains APC Loss and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

APC is altered in 8.92% of melanoma patients with APC Loss present in 0.18% of all melanoma patients [4].

APC Loss is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains APC Loss and melanoma as inclusion criteria, 1 is phase 1 (0 open) [5].

APC is altered in 11.81% of malignant solid tumor patients with APC Loss present in 0.16% of all malignant solid tumor patients [4].

APC Loss is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains APC Loss and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [5].

APC is altered in 8.59% of esophageal adenocarcinoma patients with APC Loss present in 0.15% of all esophageal adenocarcinoma patients [4].

APC Loss is an inclusion criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains APC Loss and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

APC is altered in 6.55% of gastric adenocarcinoma patients with APC Loss present in 0.13% of all gastric adenocarcinoma patients [4].

APC Loss is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains APC Loss and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

APC is altered in 5.39% of non-small cell lung carcinoma patients with APC Loss present in 0.09% of all non-small cell lung carcinoma patients [4].

APC Loss is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains APC Loss and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

APC is altered in 6.91% of bladder carcinoma patients with APC Loss present in 0.07% of all bladder carcinoma patients [4].

APC Loss is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains APC Loss and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

APC is altered in 2.18% of sarcoma patients with APC Loss present in 0.06% of all sarcoma patients [4].

APC Loss is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains APC Loss and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

APC is altered in 2.22% of breast carcinoma patients with APC Loss present in 0.05% of all breast carcinoma patients [4].

APC Loss is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains APC Loss and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

APC is altered in 2.59% of pancreatic carcinoma patients with APC Loss present in 0.04% of all pancreatic carcinoma patients [4].

APC Loss is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains APC Loss and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

APC is altered in 7.93% of adenocarcinoma of the gastroesophageal junction patients [4].

APC Loss is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains APC Loss and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [5].

APC Loss is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains APC Loss and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [5].

APC is altered in 3.17% of anaplastic ependymoma patients [4].

APC Loss is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains APC Loss and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [5].

APC is altered in 10.56% of anaplastic oligodendroglioma patients [4].

APC Loss is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains APC Loss and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [5].

APC Loss is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains APC Loss and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [5].

APC is altered in 4.76% of anaplastic pleomorphic xanthoastrocytoma patients [4].

APC Loss is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains APC Loss and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

APC Loss is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains APC Loss and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

APC is altered in 3.33% of diffuse glioma patients [4].

APC Loss is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains APC Loss and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

APC Loss is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains APC Loss and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [5].

APC Loss is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains APC Loss and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) [5].

APC Loss is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains APC Loss and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [5].

APC is altered in 2.56% of ependymoma patients [4].

APC Loss is an inclusion criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains APC Loss and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [5].

APC Loss is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains APC Loss and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [5].

APC is altered in 3.52% of esophageal squamous cell carcinoma patients [4].

APC Loss is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains APC Loss and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

APC Loss is an inclusion criterion in 1 clinical trial for gastric squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains APC Loss and gastric squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

APC is altered in 3.22% of head and neck carcinoma patients [4].

APC Loss is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains APC Loss and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

APC is altered in 3.96% of high-grade glioma, NOS patients [4].

APC Loss is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains APC Loss and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [5].

APC Loss is an inclusion criterion in 1 clinical trial for intracranial primitive neuroectodermal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains APC Loss and intracranial primitive neuroectodermal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

APC is altered in 3.53% of malignant glioma patients [4].

APC Loss is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains APC Loss and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

APC Loss is an inclusion criterion in 1 clinical trial for medulloblastoma, SHH-activated, of which 1 is open and 0 are closed. Of the trial that contains APC Loss and medulloblastoma, SHH-activated as inclusion criteria, 1 is phase 1 (1 open) [5].

APC is altered in 9.09% of pineoblastoma patients [4].

APC Loss is an inclusion criterion in 1 clinical trial for pineoblastoma, of which 1 is open and 0 are closed. Of the trial that contains APC Loss and pineoblastoma as inclusion criteria, 1 is phase 4 (1 open) [5].